Bilberry-containing Capsules for Dry Eye Mitigation
Study Details
Study Description
Brief Summary
This study investigates whether the oral intake of a bilberry capsule product may relieve dry eye symptoms. Participants will be aged between 20 - 65 years of age, with confirmed diagnosis of dry eye status. The participants will be assessed for several parameters and asked to take 4 bilberry capsules per day for 30 days. The parameters will include ocular surface health, tear volume, tear quality, intraocular pressure, and tear compositions. After the 30 days are completed, the participants will be assessed again for the same parameters.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
This investigation is a randomized, double-blind study. Subjects with confirmed diagnosis of dry eye are randomly assigned to group A or group B, and asked to orally intake 4 capsules of either bilberry product or placebo per day.The group A will have bilberry product for 30 days, have a 20-day washout period, and then have placebo for another 30 days. The group B will have placebo for 30 days, have a 20-day washout period, and then have bilberry product for another 30 days. All participants will be assessed for parameters, including intraocular pressure, ocular surface health, tear film breakup time (TBUT), tear volume (Schirmer's test), tear composition (Na+, K+, Cl- ions), tear osmolarity, ocular surface impression cytology, and ocular surface disease index (OSDI). The assessments are conducted immediately before the first 30-day and immediately after the second 30-day oral intake period. The parameters are used to compare and evaluate whether the bilberry product can relieve dry eye symptoms.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Group A-test samples This group will be given test bilberry capsule for 30 days and then have a washout period for 20 days. |
Dietary Supplement: Bilberry capsule product
A specific bilberry capsule product, containing bilberry dried extracts at 23.2 mg and bilberry powder at 3.2 mg will be given to participants for oral intake for 30 days. 30 days of Bilberry capsule product or placebo with crossover to the other.
Dietary Supplement: Placebo(starch)
30 days of placebo or Bilberry capsule product with crossover to the other.
|
Placebo Comparator: Group A-placebo This group will be given placebo for 30 days and then have a washout period for 20 days. |
Dietary Supplement: Bilberry capsule product
A specific bilberry capsule product, containing bilberry dried extracts at 23.2 mg and bilberry powder at 3.2 mg will be given to participants for oral intake for 30 days. 30 days of Bilberry capsule product or placebo with crossover to the other.
Dietary Supplement: Placebo(starch)
30 days of placebo or Bilberry capsule product with crossover to the other.
|
Outcome Measures
Primary Outcome Measures
- Change From Baseline of Schirmer's Test Value at Day 31 [on baseline and day31]
To assess tear secretion volume. The amount of tears are measured in total millimeters after 5 minutes has elapsed. Lower measurement indicates presence of dry eye disease.
- Change From Baseline of Tear Film Breakup Time at Day 31 [on baseline and day31]
Tear Break-Up Time is a measurement in seconds of tear film stability. The shorter the Tear Break-Up Time, the lower the tear film stability. Less than 10 seconds = dry eye disease; lower score indicates worse disease.
- Change From Baseline of Ocular Surface Index at Day 31 [on baseline and day31]
To assess the health status with Fluorescein stain. Scale ranges from 0 to 3, where grade 0 = None, 3 = Severe
Secondary Outcome Measures
- Change From Baseline of Tear Contents at Day 31 [on baseline and day31]
Determination of changes in osmolality and ion content for test groups of sample or placebo.
- Change From Baseline of Ocular Surface Impression Cytology at Day 31 [on baseline and day31]
To assess the status of conjunctival goblet cells and epithelium.
- Change From Baseline of Ocular Surface Disease Index Score at Day 31 [on baseline and day31]
A questionnaire to assess the health status on ocular surface, with higher scores indicating greater disability.
- Change From Baseline of Intraocular Pressure at Day 31 [on baseline and day31]
To determine the effects of intervention on intraocular pressure.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
aged between 20 and 65 years
-
with Schirmer's test results between 5 - 10 mm or Tear Film Break Up Time less than 10 seconds
-
Ocular Surface Disease Index more than 25
Exclusion Criteria:
-
evident ocular diseases such as cornea disease, cataract, vitreous degeneration, glaucoma, and retinopathy.
-
diabetes
-
hypertension
-
or other chronic diseases or belong to vulnerable groups(pregnancy woman, prisoner, ethical minorities, economic or educationally disadvantaged subjects, disabled individuals such as those at terminal stage of tumorigenesis, blindness, terminal ill individuals)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Jen-Ai Hospital | Taichung | Taiwan | 412 |
Sponsors and Collaborators
- Chung Shan Medical University
- Glory Kingdom Corporation
Investigators
- Principal Investigator: David Pei-Cheng Lin, PhD, Chung Shan Medical University
Study Documents (Full-Text)
None provided.More Information
Publications
- Brito-Zeron P, Ramos-Casals M; EULAR-SS task force group. Advances in the understanding and treatment of systemic complications in Sjogren's syndrome. Curr Opin Rheumatol. 2014 Sep;26(5):520-7. doi: 10.1097/BOR.0000000000000096.
- Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984 Apr;27(4):459-61. doi: 10.1002/art.1780270415. No abstract available.
- Kosehira M, Machida N, Kitaichi N. A 12-Week-Long Intake of Bilberry Extract (Vaccinium myrtillus L.) Improved Objective Findings of Ciliary Muscle Contraction of the Eye: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Trial. Nutrients. 2020 Feb 25;12(3):600. doi: 10.3390/nu12030600.
- Masmali AM, Purslow C, Murphy PJ. The tear ferning test: a simple clinical technique to evaluate the ocular tear film. Clin Exp Optom. 2014 Sep;97(5):399-406. doi: 10.1111/cxo.12160.
- Ozawa Y, Kawashima M, Inoue S, Inagaki E, Suzuki A, Ooe E, Kobayashi S, Tsubota K. Bilberry extract supplementation for preventing eye fatigue in video display terminal workers. J Nutr Health Aging. 2015 May;19(5):548-54. doi: 10.1007/s12603-014-0573-6.
- Schrader S, Mircheff AK, Geerling G. Animal models of dry eye. Dev Ophthalmol. 2008;41:298-312. doi: 10.1159/000131097.
- Sullivan DA, Krenzer KL, Sullivan BD, Tolls DB, Toda I, Dana MR. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? Invest Ophthalmol Vis Sci. 1999 May;40(6):1261-5.
- The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007 Apr;5(2):75-92. doi: 10.1016/s1542-0124(12)70081-2.
- Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol. 1975 Nov;59(11):667-9. doi: 10.1136/bjo.59.11.667.
- 111-73